Key takeaways
- Selank is a synthetic heptapeptide built from seven amino acids, modeled on the naturally occurring immune peptide tuftsin and studied mainly for anxiety and stress-related symptoms.
- Laboratory work suggests it acts as a positive modulator of the brain's GABA system, the same broad pathway that conventional anti-anxiety medications target.
- In one rat study, Selank enhanced the calming effect of diazepam under chronic stress.
- Human evidence comes from a small set of Russian clinical trials, including studies in generalized anxiety and neurasthenia where its anxiolytic effect was comparable to benzodiazepines such as medazepam and phenazepam, with a milder side-effect profile.
- Because of its tuftsin lineage, Selank has also been studied for immune-signaling and nootropic (attention and memory) effects.
- SCR coordinates any peptide consideration through licensed physicians, who decide whether it is appropriate for a given individual.
What Selank Is
Selank is a synthetic peptide developed in Russia and studied mainly for anxiety and stress-related symptoms. It is a heptapeptide, meaning it is built from seven amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro), and it is modeled on tuftsin, a naturally occurring peptide fragment with roles in immune signaling.
Because it is a tuftsin analogue, researchers have studied Selank not only for its calming effects but also for related effects on mood, attention, and immune signaling. In the literature it is most often described as an anxiolytic peptide, a compound aimed at lowering anxiety.
How It Is Thought to Work
The proposed mechanism for Selank centers on its origin as a tuftsin analogue. A 2018 laboratory study in Protein and Peptide Letters reported that Selank acts as a positive allosteric modulator of GABA receptors, meaning it enhances the activity of the brain's main calming (GABA) system. This is the same broad pathway that benzodiazepines act on, though the binding appears to work differently, which the authors suggest may explain why Selank does not carry the same dependence and sedation profile as those drugs.
A 2017 study in rats added a behavioral piece to that picture, reporting that Selank enhanced the anxiolytic effect of diazepam under conditions of chronic stress.
The wider context comes from a 2017 review of tuftsin and its analogues in Current Medicinal Chemistry, which places Selank within a family of tuftsin-derived peptides studied for immune-modulating, anti-inflammatory, and related activity. That lineage is why Selank has been examined for effects beyond anxiety, including attention and immune signaling. This work describes biology and animal behavior, so it points to how Selank may act in people without establishing the same effect.
The Evidence, Tier by Tier
The evidence base for Selank is best understood in tiers, from mechanism to animals to people. At the mechanism level, the 2018 receptor study and the 2017 tuftsin review describe how Selank engages the GABA system and where it sits among related peptides. At the preclinical level, the 2017 rat study showed it potentiating the calming effect of diazepam under chronic stress.
At the clinical level, the human data come from a small set of trials run in Russia. A 2008 study in generalized anxiety disorder and neurasthenia compared Selank with the benzodiazepine medazepam in 62 patients and reported a comparable anxiolytic effect, with Selank also showing antiasthenic and mild stimulant effects. A 2014 comparative trial of 60 patients with phobic-anxiety and somatoform disorders compared Selank with phenazepam and reported a pronounced anxiolytic effect plus a mild nootropic effect, with the calming benefit persisting for about a week after the last dose. These are small studies concentrated in a few research groups rather than large, independent international trials. The early human signal is consistent, but the body of evidence remains limited.
What It Is Being Explored For
Given the available research, Selank is most often discussed in the context of anxiety, stress resilience, and related mood and cognitive symptoms. The trials also describe a nootropic angle, meaning possible support for attention and mental clarity, and the tuftsin lineage has prompted interest in immune-related signaling, though that line of work is earlier still.
Whether a peptide like Selank is appropriate for any individual depends on a full clinical picture, existing medications, and a physician's judgment. SCR coordinates any peptide consideration through licensed physicians who make that call on an individual basis.
The evidence
Selected peer-reviewed references, each verified against PubMed. Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Selank is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.